Table 4.
Treatment summary of eyes with serous retinal detachment
| Eye | Sex | Age (yrs) | DSM/Inferior staphyloma | BCVA before injection (logMAR) | Number of injections | Type of anti-VEGF agent | BCVA 1 month after last injection (logMAR) |
SRD status 1 month after last injection |
BCVA at last visit (logMAR) |
SRD status At last visit, compared to 1 month after last injection |
Follow-up period (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 56 | inferior staphyloma | 0.52 | 8 |
bevacizumab × 6, aflibercept × 2 |
0.52 | increased | 0.52 | decreased but remaining | 85 |
| 2 | M | 59 | inferior staphyloma | 0.30 | 2 | bevacizumab × 2 | 0.30 | stationary | 0.22 | stationary | 17 |
| 3 | F | 76 | inferior staphyloma | 1.00 | 2 | bevacizumab × 2 | 0.70 | decreased but remaining | 1.10 | increased | 58 |
| 4 | F | 47 | DSM | 0.05 | 2 | bevacizumab × 2 | 0.05 | stationary | 0.22 | increased | 26 |
| 5 | F | 37 | DSM | 0.70 | 3 | bevacizumab × 3 | 0.52 | stationary | 0.70 | regressed | 27 |
| 6 | F | 50 | inferior staphyloma | 1.00 | 2 | bevacizumab × 2 | 0.82 | stationary | 1.70 | regressed | 79 |
| 7 | F | 44 | DSM | 0.30 | 2 | bevacizumab × 2 | 0.40 | decreased but remaining | 0.40 | stationary | 167 |
| 8 | F | 50 | DSM | 0.22 | 2 | bevacizumab × 1, ranibizumab × 1 | 0.22 | regressed | 0.22 | regressed stationary | 50 |
| 9 | F | 59 | inferior staphyloma | 0.30 | 3 | aflibercept × 3 | 0.30 | stationary | 0.30 | stationary | 10 |
| 10 | F | 47 | inferior staphyloma | 0.52 | 1 | bevacizumab × 1 | 0.70 | stationary | 0.70 | increased | 5 |
| 11 | M | 54 | inferior staphyloma | 0.40 | 1 | bevacizumab × 1 | 0.40 | stationary | 0.40 | regressed | 38 |
| 12 | F | 55 | inferior staphyloma | 0.70 | 2 | aflibercept × 2 | 0.70 | decreased but remaining | 0.10 | increased | 9 |
yrs years, M male, F female, DSM dome-shaped macula, BCVA best corrected visual acuity, logMAR logarithm of minimal angle resolution, SRD serous retinal detachment